GlassScriptPhysician profile
Anil M Patel
NPI 1396034369
$14,269.39
in general payments reported to CMS, 2019-2025
39 companies · $3,732 in 2025
The $3,732 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $614 · 2021: $1,215 · 2022: $2,469 · 2023: $2,553 · 2024: $2,425 · 2025: $3,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,175 · Consulting Fee: $1,446 · Education: $89.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,174.59 |
| Consulting Fee | $1,446.00 |
| Education | $89.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,702.35 | 2020-2025 | |
| Glaxosmithkline, LLC. | $2,452.19 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,066.92 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,261.40 | 2019-2025 | Dupixent |
| Optinose US, INC. | $502.29 | 2019-2025 | |
| Abbvie INC. | $462.52 | 2021-2024 | |
| Genentech USA, INC. | $460.19 | 2019-2025 | Xolair |
| Alk-Abello, INC | $452.37 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Kaleo, INC. | $445.40 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $422.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $369.44 | 2020-2025 | Takhzyro, Eohilia |
| Amgen INC. | $296.96 | 2021-2024 | Tezspire |
| Aimmune Therapeutics, INC. | $295.36 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $269.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.98 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $219.53 | 2024-2025 | Haegarda, Hizentra, Andembry |
| Grifols USA, LLC | $143.06 | 2024-2025 | Xembify |
| Shire North American Group INC | $122.46 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $120.93 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $120.69 | 2019-2021 | |
| Circassia INC. | $96.74 | 2019 | |
| Horizon Therapeutics Plc | $86.70 | 2022 | |
| Organon LLC | $75.80 | 2025 | Vtama |
| Incyte Corporation | $73.71 | 2021-2023 | Opzelura |
| Covis Pharma Gmbh | $70.26 | 2021 | |
| Mallinckrodt Hospital Products INC. | $57.89 | 2024 | Acthar |
| Hikma Pharmaceuticals USA | $57.16 | 2024-2025 | Ryaltris |
| Blueprint Medicines Corporation | $50.95 | 2023-2025 | Ayvakit |
| Pharming Healthcare, INC. | $47.49 | 2023-2025 | Ruconest |
| Greer Laboratories, INC. | $39.92 | 2025 | Oralair |
| Phadia US INC. | $37.08 | 2022-2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $27.03 | 2025 | Xhance |
| Cycle Pharmaceuticals INC | $26.96 | 2025 | Sajazir |
| Leo Pharma INC. | $22.95 | 2022 | |
| Lilly USA, LLC | $20.02 | 2024 | Ebglyss |
| Uswm, LLC | $16.13 | 2021 | |
| Biocryst US Sales Co., LLC | $16.02 | 2023 | Orladeyo |
| Bio Products Laboratory USA, INC. | $15.48 | 2021 | |
| Allergan, INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.